ARBELE RECEIVES FDA ORPHAN DRUG DESIGNATION FOR ARB1002, AN ANTI-CDH17 ANTIBODY-DRUG CONJUGATE FOR THE TREATMENT OF PANCREATIC CANCER

Reuters · 3d ago

Please log in to view news